ADC Franchise page edits 12 2017

Investigational ADC Franchise

The investigational Antibody Drug Conjugate (ADC) Franchise of the Daiichi Sankyo Cancer Enterprise is built around our ADC proprietary technology, which is being researched across multiple types of cancer. Our proprietary linker and payload technologies have been specifically designed to potentially address various limitations of two critical components of an ADC: the payload and linker.

Daiichi Sankyo Proprietary ADC Technology

ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy directly to cancer cells. An ADC consists of three components:

1) a monoclonal antibody

2) a cytotoxic chemotherapy payload

3) a linker that joins the two together

Using expertise in both protein engineering and medicinal chemistry, our team of exceptional scientists has methodically designed proprietary ADC technology to target and deliver chemotherapy inside cancer cells and reduce systemic exposure to the cytotoxic payload (or chemotherapy) compared to the way that chemotherapy is commonly delivered. The cornerstone of our ADC Franchise is a proprietary payload and linker-payload technology, which consists of:

  • Payload: DXd, a novel topoisomerase I inhibitor
  • Linker: A proprietary tetrapeptide-based linker that joins the antibody and payload together, and is designed to be broken down by lysosomal enzymes such as cathepsins, which are highly expressed in tumor cells

Our investigational ADC Franchise currently consists of seven novel ADCs, including DS-8201 in pivotal phase 2 clinical development; U3-1402 in phase 1/2 clinical development, DS-1062 in phase 1 development; DS-7300, DS-6157 and DS-6000 in preclinical development; and TA-MUC1 in discovery

We are open to partnership opportunities with external companies to combine our linker-payload technology with other monoclonal antibodies as well as collaborations with other compounds to study in combination with our ADC assets.

These are investigational agents and have not been approved by the FDA or any other worldwide regulatory agency as a treatment for any indication. Safety and efficacy have not been established.


Antibody Drug Conjugate (ADC) Franchise




DS-8201 is the lead product in the investigational ADC Franchise of the Daiichi Sankyo Cancer Enterprise. A broad and comprehensive clinical development program is currently underway with DS-8201:

 Phase 3 Clinical Studies

• DESTINY-Breast03 – DS-8201 versus ado-trastuzumab emtasine (T-DM1) in HER2-positive unresectable and/or metastatic brest cancer previously treated with trastuzumab and a taxane (North America, EU and Asia)
• DESTINY-Breast02 – DS-8201 versus investigators’s choice in HER2-positive unresectable and/or metastatic breast cancer previously treated with standard of care HER2 therapies includng T-DM1 (North America, South America, EU and Asia)

Pivotal Phase 2 Clinical Studies

• DESTINY-Breast01 – DS-8201 for HER2-positive unresectable and/or metastatic breast cancer resistant or refractory to T-DM1 (North America, EU and Asia)
• DESTINY-Gastric01 –  DS-8201for HER2-positive advanced gastric cancer resistant or refractory to trastuzumab (Japan and South Korea)

Phase 2 Clinical Studies

•  Colorectal Cancer: DS-8201 for HER2 advanced colorectal cancer previously treated with at least two prior lines of standard treatment (North America)
•  Non-Small Cell Lung Cancer: DS-8201 for unresectable and/or metastatic non-squamous HER2-overexpressing or HER2-mutated non-small cell lung cancer that has progressed after one or more prior therapies (North America, EU and Japan)

Phase 1 Clinical Studies

• Breast and Bladder Cancers: DS-8201 in combination with nivolumab in HER2-expressing breast and bladder cancers in the US and EU
• Solid Tumors: DS-8201 for HER2-expressing advanced/unresectable or metastatic solid tumors (US and Japan)

DS-8201 has been granted Breakthrough Therapy designation for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-DM1), and Fast Track designation for the treatment of HER2-positive unresectable and/or metastatic breast cancer in patients who have progressed after prior treatment with HER2-targeted therapies including T-DM1 by the U.S. Food and Drug Administration (FDA).

DS-8201 has also been granted SAKIGAKE Designation by the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of HER2-positive advanced gastric or gastroesophageal junction cancer.






U3-1402 is an investigational and potential first-in-class HER3-targeting ADC currently in phase 1/2 development for HER3-expressing metastatic or unresectable breast cancer in Japan and phase 1 development for metastatic or unresectable epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer in the U.S.




DS-1062 is an investigational TROP2-targeting ADC currently in phase 1 development for unresectable advanced non-small cell lung cancer.

AML Franchise more stories content

More Stories

AML Franchise

Our AML Franchise is looking to change the standard of care for patients with acute myeloid leukemia (AML), a fast-growing form of leukemia that has the lowest 5-year survival rate of all leukemias with little change in the treatment of AML for the past 30 years.

read more ...